In Silico Evaluation via Virtual Screening, ADMET Profiling and Molecular Dynamics Simulations: Synthesis and Biological Activity Analysis of a Novel Antitumor PI3K Inhibitor.
- 1School of Chemistry and Chemical Engineering, Qilu Normal University, Jinan 250200, China.
- 2Tianjin Key Laboratory of Technologies Enabling Development of Clinical Therapeutics and Diagnostics, School of Pharmacy, Tianjin Medical University, Tianjin 300070, China.
Abstract
The PI3K plays a crucial role in cancer progression, and the development of PI3K inhibitors has always been a hot research direction in oncology. Through virtual screening and docking, potential lead compounds were identified. ADMET prediction revealed that KTC101 possesses superior pharmacokinetic profile. Molecular dynamics simulations indicated that compound KTC101 could stably bind to PI3Kδ, with a binding free energy of -374.627 kJ/mol. Analysis of the metabolism of KTC101 revealed that this compound could undergo diverse phase I metabolic reactions catalyzed by hepatic CYP450 enzymes to form highly polar metabolites, indicating its strong metabolic potential and easy metabolic clearance in vivo. Then it was synthesized and evaluated for kinase inhibitory activity and antiproliferative effects in HNSCC cell lines. KTC101 was first reported as a PI3K inhibitor, with IC₅₀ values of 191.23 ± 40.84 nM, 23.30 ± 5.68 nM, and 146.20 ± 21.82 nM for PI3Kα, PI3Kδ and PI3Kγ, respectively, and demonstrated dose-dependent inhibition of cancer cell growth in vitro, with IC₅₀ values of 4.1 ± 0.73 μM for HSC3 cells and 2.2 ± 0.11 μM for HSC4 cells. It exhibited inhibitory activity against PI3K, showing greater inhibitory potency toward PI3Kδ. This study demonstrates the anti-tumor potential of KTC101.
Related
- Metabolomic Profiling Screening for Molecular Level Associations Related to Cashmere Quality Related Phenotypic Types in Liaoning Cashmere Goats
- Metabolic Profiling, Antioxidant Activity, and Mechanistic Insights of Chicory from Northern and Southern China: Integrating Metabolomics, Machine Learning, Molecular Docking, Molecular Dynamics Simulations, and In Vitro Assays
- Multistep synthesis of novel indole–benzimidazole hydrazone hybrids as xanthine oxidase inhibitors: In-Vitro evaluation, molecular docking, MD simulations and DFT studies
- Identification of novel serotonin transporter (SERT) inhibitors via large-scale machine learning-based virtual screening and molecular dynamics simulations
- Design, synthesis, and biological evaluation of novel 4,5-diaryl-1,2,3-thiadiazole derivatives: anticancer activity and molecular docking studies
BibTeX
@article{jia2026silico,
title = {{In Silico Evaluation via Virtual Screening, ADMET Profiling and Molecular Dynamics Simulations: Synthesis and Biological Activity Analysis of a Novel Antitumor PI3K Inhibitor.}},
author = {Wenqing Jia and Yukui Ma and Zhe Zhang},
journal = {Biology},
year = {2026},
month = oct,
doi = {10.3390/biology15191742},
url = {https://europepmc.org/article/MED/42883415},
note = {CC BY},
}
RIS
TY - JOUR
TI - In Silico Evaluation via Virtual Screening, ADMET Profiling and Molecular Dynamics Simulations: Synthesis and Biological Activity Analysis of a Novel Antitumor PI3K Inhibitor.
AU - Wenqing Jia
AU - Yukui Ma
AU - Zhe Zhang
PY - 2026
DA - 2026/10/01
JO - Biology
DO - 10.3390/biology15191742
UR - https://europepmc.org/article/MED/42883415
AB - The PI3K plays a crucial role in cancer progression, and the development of PI3K inhibitors has always been a hot research direction in oncology. Through virtual screening and docking, potential lead compounds were identified. ADMET prediction revealed that KTC101 possesses superior pharmacokinetic profile. Molecular dynamics simulations indicated that compound KTC101 could stably bind to PI3Kδ, with a binding free energy of -374.627 kJ/mol. Analysis of the metabolism of KTC101 revealed that this compound could undergo diverse phase I metabolic reactions catalyzed by hepatic CYP450 enzymes to form highly polar metabolites, indicating its strong metabolic potential and easy metabolic clearance in vivo. Then it was synthesized and evaluated for kinase inhibitory activity and antiproliferative effects in HNSCC cell lines. KTC101 was first reported as a PI3K inhibitor, with IC₅₀ values of 191.23 ± 40.84 nM, 23.30 ± 5.68 nM, and 146.20 ± 21.82 nM for PI3Kα, PI3Kδ and PI3Kγ, respectively, and demonstrated dose-dependent inhibition of cancer cell growth in vitro, with IC₅₀ values of 4.1 ± 0.73 μM for HSC3 cells and 2.2 ± 0.11 μM for HSC4 cells. It exhibited inhibitory activity against PI3K, showing greater inhibitory potency toward PI3Kδ. This study demonstrates the anti-tumor potential of KTC101.
SN - 2079-7737
ER -